Family Medicine · Year 3 · from Family Medicine

Case 3: Prostate Cancer Screening Discussion

Patient Demographics

  • Age: 58 years old
  • Sex: Male
  • Race: African American
  • Occupation: High school principal

Chief Complaint

"My brother was just diagnosed with prostate cancer. Should I get tested?"

History of Present Illness

Mr. Marcus Johnson is a 58-year-old African American man presenting for discussion of prostate cancer screening. His 62-year-old brother was recently diagnosed with localized prostate cancer after an elevated PSA was found during a routine physical. This has prompted significant concern, and he wants to know if he should be tested. He denies any urinary symptoms, bone pain, or weight loss. He has never had a PSA test.

Past Medical History

  • Hypertension, well-controlled
  • No prior cancers or surgeries

Family History

  • Brother: Prostate cancer, age 62, currently undergoing treatment
  • Father: Died at 78, cause unknown (no cancer history)
  • No other known family history of prostate or other cancers

Social History

  • Non-smoker
  • Occasional alcohol
  • Married, three adult children
  • Exercises regularly (walks 30 minutes daily)

Physical Examination

  • Vital Signs: BP 128/76 mmHg, HR 68, BMI 27
  • General: Healthy-appearing, no acute distress
  • Digital Rectal Examination:
  • Prostate: Normal size, smooth, symmetric
  • No nodules, no tenderness
  • Normal sphincter tone

Clinical Image

Image: Illustration depicting the shared decision-making process for prostate cancer screening, showing a balance scale weighing the potential benefits (early detection, possible mortality reduction) against harms (false positives, overdiagnosis, treatment side effects).

Image Source: Wikimedia Commons Attribution: National Cancer Institute, Public Domain URL: https://commons.wikimedia.org/wiki/File:Prostate_cancer_screening_decision.jpg

Shared Decision-Making Discussion

Risk Factors Identified:

  • African American race: 60% higher incidence and 2-3 times higher mortality than white men
  • First-degree relative with prostate cancer: approximately 2x risk
  • Combined risk factors place patient in HIGH-RISK category

Benefits of PSA Screening Discussed:

  • May detect prostate cancer earlier when potentially curable
  • Possible modest reduction in prostate cancer mortality (1-2 deaths prevented per 1,000 men screened over 10-15 years)
  • Peace of mind with negative result
  • For high-risk men, potential benefit may be greater

Harms of PSA Screening Discussed:

  • High false-positive rate leading to unnecessary biopsies
  • Biopsy complications: pain, bleeding, infection
  • Overdiagnosis of cancers that would never cause harm (estimated 20-50% of screen-detected cancers)
  • Overtreatment with associated side effects:
  • Erectile dysfunction (30-60% after treatment)
  • Urinary incontinence (10-20% after treatment)
  • Bowel problems with radiation
  • Anxiety from positive results

USPSTF Recommendation:

  • For men 55-69: Grade C (individualized decision through shared decision-making)
  • For this patient: Given high-risk status (African American + family history), professional organizations recommend initiating discussion at age 40-45 and screening may be more beneficial

Patient's Decision and Values

  • Patient expressed high value on early detection given brother's diagnosis
  • Concerned about potential cancer but also about treatment side effects
  • Understood that positive PSA does not equal cancer diagnosis
  • After thorough discussion, patient chose to proceed with PSA testing

Assessment and Plan

  1. Prostate cancer risk counseling completed with shared decision-making
  2. Patient is high-risk (African American + first-degree relative with prostate cancer)
  3. Patient elects PSA screening after informed discussion

Laboratory Ordered:

  • PSA level

Follow-Up Plan:

  • Results will be discussed at follow-up visit or by phone
  • If PSA elevated (>4 ng/mL or age-specific threshold):
  • Repeat PSA to confirm
  • Calculate free PSA ratio
  • Urology referral for consideration of multiparametric MRI and possible biopsy
  • If PSA normal:
  • Annual screening per patient preference
  • Continue shared decision-making at each visit

Documentation

  • Documented detailed discussion of risks, benefits, and alternatives
  • Patient understood the information and made informed decision
  • Written consent for PSA testing obtained

Teaching Points

  1. Shared decision-making is mandatory for prostate cancer screening - the clinician must discuss benefits AND harms
  1. African American men and those with family history are at significantly elevated risk and may benefit more from screening; professional organizations recommend earlier discussion (age 40-45)
  1. PSA is not a cancer test - it is a marker of prostate pathology (also elevated in BPH, prostatitis, instrumentation)
  1. The harms of screening include overdiagnosis and overtreatment - many detected cancers would never cause clinical harm during the patient's lifetime
  1. Active surveillance is now the preferred management for low-risk prostate cancer, avoiding immediate treatment side effects while monitoring for progression
  1. Document the shared decision-making discussion thoroughly in the medical record

Key Teaching Points Summary

Men's Health Disparities

  • Men have 5 years shorter life expectancy than women
  • Men are less likely to seek preventive care
  • Suicide rate in men is 4 times higher than women despite lower depression diagnosis rates

Prostate Conditions

  • BPH: Use IPSS scoring to guide treatment; alpha-blockers for rapid relief; 5-ARIs for larger prostates
  • PSA screening requires shared decision-making; high-risk groups benefit from earlier discussion
  • Digital rectal examination cannot reliably distinguish BPH from cancer

Erectile Dysfunction

  • Consider ED as a cardiovascular warning sign - evaluate and address risk factors
  • PDE5 inhibitors are absolutely contraindicated with nitrates
  • Lifestyle modifications (smoking cessation, weight loss, exercise) address root cause

Clinical Pearls

  • Tamsulosin: warn patients about intraoperative floppy iris syndrome before cataract surgery
  • 5-alpha reductase inhibitors reduce PSA by ~50% - must adjust when interpreting PSA results
  • Thiazide diuretics and some beta-blockers can contribute to erectile dysfunction

All cases for this lecture as Markdown